DCVMN Board

Iin has a career of more than 30 years in biopharmaceutical company, with experience in quality, operation, business development, Human Capital and transformation of the company She involved in several global partnership activities such as WHO prequalification, Developing Countries Vaccine Manufacturer Network and other bilateral partnerships.
She is also active as a volunteer in ISPE Indonesia affiliate.

Dr Morena Makhoana joined Biovac in 2004 and holds the role of Chief Executive Officer. He is a member of the Board and the Biovac Executive team.
During his tenure Biovac has attracted three successful technology transfers with global pharmaceutical companies such as Sanofi and Pfizer and more recently with DCVMN partners such as Eubiologics and Biological E. He has also led the company to be the first in South Africa to develop a local vaccine in more than 50 years.
Morena is currently spearheading Biovac’s next phase of deepening Biovac end to end vaccine capabilities as well as international expansion. These efforts are in line with African continent mission to be self-reliant on vaccine production and be pandemic ready.

Rosane Cuber Guimarães is the General Director of Bio-Manguinhos/Fiocruz, with over two decades of experience in vaccine development, production, and regulatory affairs. She coordinated the national rollout of the COVID-19 vaccine in partnership with AstraZeneca and enhanced Yellow Fever vaccine supply for national and international programs. Dr. Guimarães holds a PhD from Fiocruz and combines academic excellence with industrial leadership in global immunization.

Rachel Park has been with EuBiologics from prequalification to commercialization of Euvichol-Plus, oral cholera vaccine since 2015. She’s a director in international business at EuBiologics, responsible for marketing and collaboration with international stakeholders for its pipeline development. She was a venture capitalist funding biotechnology companies prior to joining in EuBioloigcs.

Andrew holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics, human vaccine research, business development, global registration and sales & marketing. Through Andrew’s leadership and participation, Walvax and its subsidiary companies have received several grant and/or technical supports from DCVMN, Bill & Melinda Gates Foundation, PATH, CEPI and CHAI since 2014, in addition to the global business expansion of product registration and sales in numerous countries.

Dr Sunil Gairola is the elected executive director at Serum Institute of India, (Missing bio), Responsible for vaccine quality with more than 30 years of experience in quality control, quality assurance and bioanalytic of vaccines and biosimilars. Collaborator to international initiatives of WHO, NVI, NIBSC, EDQM with interests in the harmonization of regulatory requirements of vaccines. Expert on Indian and USP Pharmacopoeia (IP) panels on vaccine and biosimilar monographs.

Senior Executive with over 30 years of leadership experience in the pharmaceutical industry, specializing in immunobiological and synthetic products across Brazil and Latin America such Eli Lilly, Astelas, Novartis Sanofi and Butantan. Renowned for building and leading high-performance teams and for designing and executing commercial, marketing, and market access strategies for product launches, repositioning, and lifecycle management. With deep expertise in public business models and PDPs within the Brazilian healthcare system. Combines strategic vision with strong innovation capabilities and talent development.

To meet un-precedented challenge posed by COVID-19, Rajinder as CEO-DCVMN is actively involved in all global strategic initiatives along with COVAX partners and industry associations to ensure equity and timely access to vaccines.
He is member of several advisory expert groups including COVAX Manufacturing & Supply Task Force Leadership Team and Market Design and Demand Intelligence pillar of PAVM.
He brings over 25 years of top management experience in the industry including Board of Directors of the Indian subsidiary of Sanofi Pasteur and. Rajinder has been Member- GAVI-PPC of as well as Vice-President, DCVMN Executive Committee.

Mr. Lobos is Engineer and MBA with 20-years’ professional experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. He has been working in vaccine companies for over 12 years. He holds a engineering degree from University of Buenos Aires.